Paradigm Biopharmaceuticals

(ASX) PAR

Current PriceA$0.15

Market CapA$86.47M

Since IPO (2015)-57%

5 Year-93%

1 Year-49%

1 Month-17%

Paradigm Biopharmaceuticals Financials at a Glance

Market Cap

A$86.47M

Revenue (TTM)

A$143.07K

Net Income (TTM)

-A$51.71M

EPS (TTM)

-A$0.09

P/E Ratio

-1.68

Dividend

A$0.00

Beta (Volatility)

0.09 (Low)

Dividend

A$0.00

Beta (Volatility)

0.09 (Low)

Price

A$0.15

Volume

1,216,350

Open

A$0.15

Price

A$0.15

Volume

1,216,350

Open

A$0.15

Previous Close

A$0.15

Daily Range

A$0.15 - A$0.16

52-Week Range

A$0.14 - A$0.48

Estimated Earnings Date

Aug 21, 2026

Dividend

A$0.00

Beta (Volatility)

0.09 (Low)

Price

A$0.15

Volume

1,216,350

Open

A$0.15

Previous Close

A$0.15

Daily Range

A$0.15 - A$0.16

52-Week Range

A$0.14 - A$0.48

Estimated Earnings Date

Aug 21, 2026

PAR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Paradigm Biopharmaceuticals

Industry

Biotechnology

Sector

Health Care

CEO

Paul John Rennie

Website

www.paradigmbiopharma.com

Headquarters

Melbourne, VIC 3000, AU

PAR Financials

Key Financial Metrics (TTM)

Gross Margin

-2%

Operating Margin

-638%

Net Income Margin

-596%

Return on Equity

-180%

Return on Capital

-6%

Return on Assets

-2%

Earnings Yield

-59.52%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$86.47M

Shares Outstanding

576.50M

Volume

1.22M

Avg. Volume

1.76M

Financials (TTM)

Gross Profit

-A$19.89K

Operating Income

-A$22.89M

EBITDA

-A$25.25M

Operating Cash Flow

-A$15.99M

Capital Expenditure

-A$5.00

Free Cash Flow

-A$15.99M

Cash & ST Invst.

A$16.82M

Total Debt

A$5.48K

Paradigm Biopharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

A$25.15K

N/A

Gross Profit

-A$51.17K

+30.3%

Gross Margin

-2.03%

N/A

Market Cap

A$86.47M

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-A$23.24M

+52.5%

EBITDA

-A$21.76M

+56.5%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

A$14.66M

-56.3%

Total Debt

A$1.01M

+248.4%

Accounts Receivable

A$6.31M

-15.0%

Inventory

A$0.00

N/A

Long Term Debt

A$873.62K

+393.5%

Short Term Debt

A$137.95K

-39.1%

Return on Assets

-1.56%

N/A

Return on Invested Capital

-5.90%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$19.65M

+61.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NYR.AXNyrada Inc.

NYR.AXNyrada Inc.A$0.44-2.22%

AHC.AXAustco Healthcare Limited

AHC.AXAustco Healthcare LimitedA$0.23+2.27%

ALA.AXArovella Therapeutics Limited

ALA.AXArovella Therapeutics LimitedA$0.07+1.52%

ACW.AXActinogen Medical Limited

ACW.AXActinogen Medical LimitedA$0.03+0.00%

AVH.AXAVITA Medical, Inc.

AVH.AXAVITA Medical, Inc.A$1.08-5.68%

RCE.AXRecce Pharmaceuticals Ltd

RCE.AXRecce Pharmaceuticals LtdA$0.50+2.04%

EMV.AXEMVision Medical Devices Ltd

EMV.AXEMVision Medical Devices LtdA$1.57-1.88%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98+0.02%

NOKNokia

NOKNokia$14.80+0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.52+0.02%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.46-0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.04-0.02%

RKLBRocket Lab

RKLBRocket Lab$102.39-0.11%

Questions About PAR

What is the current price of Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals is trading at A$0.15 per share.

What is the 52-week range for Paradigm Biopharmaceuticals?

Over the past 52 weeks, Paradigm Biopharmaceuticals has traded between A$0.14 and A$0.48.

How much debt does Paradigm Biopharmaceuticals have?

As of the most recent reporting period, Paradigm Biopharmaceuticals reported total debt of A$5.48K.

How much cash does Paradigm Biopharmaceuticals have on hand?

Paradigm Biopharmaceuticals reported A$16.82M in cash and cash equivalents in its most recent financial results.

What is Paradigm Biopharmaceuticals’s dividend yield?

Paradigm Biopharmaceuticals does not currently have a dividend yield.

Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Financials at a Glance

PAR News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Paradigm Biopharmaceuticals

PAR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Paradigm Biopharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PAR

What is the current price of Paradigm Biopharmaceuticals?

What is the 52-week range for Paradigm Biopharmaceuticals?

How much debt does Paradigm Biopharmaceuticals have?

How much cash does Paradigm Biopharmaceuticals have on hand?

What is Paradigm Biopharmaceuticals’s dividend yield?

Premium Investing Services